Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners

0:00-17:49

China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.

Publisher

BioSpace

Published

October 21, 2026

Duration

18 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#discsredemption #veradermicsvalidation #esmosheadliners #lifesciences

The Nile